弥漫性大B细胞淋巴瘤
一致性
淋巴瘤
医学
液体活检
基因分型
内科学
肿瘤科
循环肿瘤DNA
活检
国际预后指标
生存分析
癌症研究
基因型
癌症
生物
基因
遗传学
作者
Miaomiao Li,Ning Ding,Lan Mi,Yunfei Shi,Xinhua Du,Yuting Yi,Ling Yang,Weiping Liu,Jun Zhu
标识
DOI:10.1080/10428194.2021.1999441
摘要
The utility of circulating tumor DNA (ctDNA) in classifying the cell origin of diffuse large B-cell lymphoma (DLBCL) has not been explored in the Chinese population. In this study, we aimed to investigate the genetic characteristics of DLBCL based on both tumor and ctDNA sequencing and to assess the predictive value of ctDNA in DLBCL. A targeted sequencing panel of 413 genes was applied to tumor biopsies and paired plasma samples obtained from 30 patients with DLBCL before therapeutic intervention (pretreatment). The concordance between plasma genotyping classification and traditional cell-of-origin classification using tumor tissue was 80.0% (20/25). Patients with higher baseline plasma ctDNA levels had poorer survival compared to those with lower ctDNA levels (2-year progression survival rate: 40.0% vs. 80.0%, p = 0.011; 5-year overall survival rate: 30.5% vs. 70.0%, p = 0.004). Collectively, our results demonstrated that pretreatment ctDNA analysis could assist origin determination and prognosis prediction clinically.
科研通智能强力驱动
Strongly Powered by AbleSci AI